AZN vs BFLY

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

Butterfly Network (BFLY) shows a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive bankruptcy risk assessment. Despite deeply negative profitability metrics—including a -90.31% profit margin and negative ROE/ROA—the company maintains strong liquidity (Current Ratio: 4.80) and a low Debt/Equity ratio of 0.10. Revenue growth is modest at 4.50% YoY, but earnings surprises have been consistently positive in recent quarters, suggesting operational improvements. However, aggressive insider selling worth $21.71M over the past six months contradicts the 'strong_buy' analyst consensus and raises concerns about insider confidence.